Diabetic retinopathy (RD) is the most common complication of diabetes and it is the first cause of blindness in adults of developed countries. RD is a progressive pathology that affects the neurovascular unit of retina in which microvessels, glial cells and neurons are damaged as a consequence of hyperglycemia. In a previous study, our group showed that: _x000D_ _x000D_ 1) The content of glucagon-like peptide 1 (GLP-1) was decreased in diabetic retinas and,_x000D_ _x000D_ 2) GLP-1 exerted neuroprotective effects in DR experimental model. The overarching aim of this thesis is to achieve preclinical evidence which permit us the the design of clinical trials for treating early stages of DR with either agonists of GLP-1 receptor (GLP-1RAs) or inhibitors of the enzyme DPP-IV (DPP-IVi), which increase the life span of GLP-1. For this purpose, we used the experimental animal model of type 2 diabetes, the db/db mouse (BKS.Cg-Dock7m +/+ Leprdb/J).
DESARROLLO DE UN TRATAMIENTO TÓPICO EN COLIRIO PARA LA RETINOPATÍA DIABÉTICA BASADO EN EL EFECTO NEUROPROTECTOR DE GLP-1
SAMPEDRO VIDA, J. (Author). 29 Jul 2020
Student thesis: Doctoral thesis
Student thesis: Doctoral thesis